Genexine (XKRX:095700) Accumulated Depreciation : ₩-20,174 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Genexine's quarterly accumulated depreciation increased from Sep. 2023 (₩-18,106 Mil) to Dec. 2023 (₩-19,032 Mil) and increased from Dec. 2023 (₩-19,032 Mil) to Mar. 2024 (₩-20,174 Mil).

Genexine's annual accumulated depreciation increased from Dec. 2021 (₩-13,829 Mil) to Dec. 2022 (₩-14,911 Mil) and increased from Dec. 2022 (₩-14,911 Mil) to Dec. 2023 (₩-19,032 Mil).

Genexine Accumulated Depreciation Historical Data

The historical data trend for Genexine's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Accumulated Depreciation Chart

Genexine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-14,364.38

-16,029.97

-13,829.24

-14,910.89

-19,031.77

Genexine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-15,989.20	-17,096.93	-18,105.71	-19,031.77	-20,174.43

Genexine Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Genexine Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Genexine's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines